Navigation Links
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Date:12/9/2008

re patients frequently suffer episodes of acute decompensated heart failure (ADHF) which require hospitalization. For Americans over 65 years of age, ADHF is the most frequent cause of hospital admission. In recent years, 2.4 million patients in the US were hospitalized with a primary or secondary discharge code of ADHF and an average hospital stay of 4.3 days.

About CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of ADHF. CD-NP was rationally designed by scientists at the Mayo Clinic's Cardiorenal Research Labs. Current therapies for ADHF, including B-type natriuretic peptide, have been associated with favorable pharmacologic effects, but have also been associated with hypotension and decreased renal function which limit their utility in clinical practice. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing or preserving renal function. The Company believes that these biochemical features, together with preclinical and preliminary clinical data in patients with heart failure, suggest that CD-NP may have a favorable safety and efficacy profile relative to current therapies for ADHF. In addition to an initial indication for ADHF, CD-NP has potential utility in other indications which include preservation of cardiac function subsequent to acute myocardial infarction (AMI), and prevention of renal damage subsequent to cardiac surgery. We expect to initiate a Phase 2b study in patients with acute heart failure in 2009.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric pept
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
9. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
10. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
11. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Smith & Nephew (LSE:SN, ... technology business, today announced its entry into the ... Lesser Toe Repair System. Comprised of three separate ... metatarsophalangeal (MTP) ligament repair and reconstruction, a metatarsal ... proximal Inter-phalanges (PIP) fusion, also known as hammer ...
(Date:7/31/2014)... 2014 Although RNA-Sequencing is a ... transcriptome-wide analyses appearing around 2008, RNA-Sequencing has rapidly ... measurement. In the last several years, assays have ... with smaller input amounts, process degraded RNA, and ... On the bioinformatics side, there have been improvements ...
(Date:7/31/2014)... Boston, MA (PRWEB) July 31, 2014 ... ) finds itself flush with innovative adult stem cell ... patents and has three additional patent applications ... Office. , The patented inventions address two of the ... and regenerative medicine. Adult stem cells are difficult ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
Breaking Biology Technology:Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... aims to reach five million in five years, ... DGX ), the nation,s leading provider of diagnostic,testing information ... designed to help increase compliance with take-home colorectal,screening tests. ... Have,the Guts?," the campaign aims to break down barriers ...
... To Be Held Tuesday, April 1, 2008 At 10:00 a.m. Eastern ... ... March 31 Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reported ... highlights., (Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO ), "2007 was a ...
... ... 31 Cephalon, Inc.,(Nasdaq: CEPH ) has scheduled its regular quarterly earnings conference call,covering first ... ... Q1 2008 results will be distributed by PRNewswire 4:50 p.m. EDT To ...
Cached Biology Technology:Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 2Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 3Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo 4Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 2Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 3Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 4Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 5Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 6Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 7Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 8Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 9Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 10
(Date:7/31/2014)... same week that the U.S. surgeon general issued a ... at Montana State University published a paper breaking new ... every cell responds when exposed to ultraviolet (UV) ... damage by the UV rays found in sunlight. This ... degenerative eye diseases. , "Our paper advances foundational ...
(Date:7/31/2014)... White, brown and beige adipocytes, or fat cells, are ... functions and each plays its own role in metabolism. ... far the most prevalent. Its primary function is energy ... energy to generate heat but are only found in ... adipocytes, which represent a special type of brown adipocytes, ...
(Date:7/30/2014)... is paving the way for a breakthrough that ... troops exposed to poisonous chemicalsparticularly those in pesticides ... the current issue of the journal ChemBioChem ... are compounds commonly used in pesticides and warfare ... School of Engineering Associate Professor of Chemical and ...
Breaking Biology News(10 mins):New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3Hope for the overweight 2Engineering a protein to prevent brain damage from toxic agents 2
... The death of insulin-producing beta cells in the pancreas ... Texas now have discovered a new way that these cells ... other pancreatic cells. "Our study shows that neighboring cells ... This was an unexpected finding," said Franco Folli, M.D., Ph.D., ...
... (NIFA) has awarded a consortium of land-grant institutions in ... Coordinated Agricultural Grant to study the effects of climate ... announcement, Paul Winistorfer, dean of the College of Natural ... climate change mitigation and adaptation as it relates to ...
... to increased well-being in adulthood, new research finds. ... childhood and mental health problems, but little research has examined ... time, researchers from the University of Cambridge and the MRC ... between a positive adolescence and well-being in midlife. Using ...
Cached Biology News:Scientists find a new way insulin-producing cells die 2Virginia Tech shares in grant to study effects of climate change on southern pine forests 2Virginia Tech shares in grant to study effects of climate change on southern pine forests 3Virginia Tech shares in grant to study effects of climate change on southern pine forests 4Happy children make happy adults 2
... is a direct antibiotic-based selection system for ... colony survival, eliminating the need for costly ... provides close to 100% accuracy in recombinant ... for robot colony picking. This cloning ...
...
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: